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Abstract
Background: Celiac disease is a multiform, challenging condition characterized by extremely variable features. Our
goal was to define clinical, serological and histopathological findings in a large cohort of celiacs diagnosed in a single
referral center.
Methods: From January 1998 to December 2012, 770 patients (599 females, median age 36 years, range 18-78 years)
were diagnosed as celiacs at St.Orsola-Malpighi Hospital (Bologna, Italy). The clinical phenotypes were classified as:
1) classical (malabsorption syndrome); 2) non-classical (extraintestinal and/or gastrointestinal symptoms other
than diarrhea); 3) subclinical. Serology, duodenal histology, comorbidities, response to gluten-free diet and complications
were evaluated.
Results: Disease onset was symptomatic in 610 patients (79%), while 160 celiacs showed a subclinical phenotype. In the
symptomatic group the non-classical prevailed over the classical phenotype (66% vs 34%). Diarrhea was found in 27%,
while other gastrointestinal manifestations were bloating (20%), aphthous stomatitis (18%), alternating bowel habit
(15%), constipation (13%) and gastroesophageal reflux disease (12%). Extraintestinal manifestations included osteopenia/
osteoporosis (52%), anemia (34%), cryptogenic hypertransaminasemia (29%) and recurrent miscarriages (12%). Positivity
for IgA tissue transglutaminase antibodies was detected in 97%. Villous atrophy was found in 87%, while 13% had minor
lesions consistent with potential celiac disease. A large proportion of patients showed autoimmune disorders,
i.e. autoimmune thyroiditis (26.3%), dermatitis herpetiformis (4%) and diabetes mellitus type 1 (3%). Complicated
celiac disease was very rare.
Conclusions: Our study demonstrates that the clinical profile of celiac disease changed over time with an increasing
rate of non-classical and subclinical phenotypes.
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Background
Until the end of the second millennium, the classic view
of celiac disease (CD) was that of a rare food intolerance
characterized by villous atrophy and overt malabsorption
mainly affecting pediatric patients. Recently, CD has mark-
edly changed due to considerable advances in the know-
ledge of its pathogenic and diagnostic aspects [1,2]. CD is
now an established autoimmune disorder triggered by
gluten which activates an immune reaction against the
CD autoantigen, i.e. tissue transglutaminase (TG2), in
genetically predisposed subjects [3]. The genetic suscepti-
bility to CD is confirmed by its occurrence in about 10%
of first-degree relatives and by its close linkage with histo-
compatibility leukocyte antigens (HLA)-DQ2 and -DQ8
[4]. Environmental factors such as breastfeeding, timing of
weaning, viral/bacterial infections and microbiota changes
can play a role in the onset of CD at any age [5-8].
The identification of biomarkers, e.g. antibodies to
endomysium (EmA) [9] and to TG2 (anti-TG2) [10], has
changed the epidemiology of CD from a rare to a frequent
condition with an expected prevalence higher than 1% in
the worldwide population. Nonetheless, the majority of
patients with CD remain undiagnosed leaving the celiac
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‘iceberg’ still submerged [11]. Serological screening has
allowed an early CD diagnosis in its preclinical stage
with the result that symptom presentation has radically
changed compared to the past [12,13]. Indeed, CD is less
commonly detected in patients with diarrhea, rather it
occurs frequently in patients with other gastrointestinal
symptoms, i.e. constipation and bloating, as well as with
extra-intestinal manifestations and even in asymptomatic
patients [14]. The different mode of presentation has led
experts to elaborate the Oslo classification which subdivides
CD in symptomatic, i.e. “classical” and “non-classical”, vs.
clinically silent, i.e. “subclinical”, phenotypes [15].
In this study we retrospectively examined the clinical
presentation of a large cohort of consecutive CD adult
patients diagnosed in a single Italian referral center during
a 15-year period. Our primary goal was to verify whether
non-classical and subclinical CD increased over time com-
pared to the classical CD. Furthermore, we aimed to de-
fine serology, histopathology, response to gluten free diet
(GFD) and occurrence of complications in CD.
Methods
This is a retrospective paper assessing patients from
January 1998 to December 2012: 770 CD patients (599
females, F/M ratio 3.5:1, median age at diagnosis 36
years, range 18-78 years) were consecutively diagnosed
at the referral center of St. Orsola-Malpighi University
Hospital (Bologna, Italy). All patients included in the
study gave written informed consent to publish their own
data when they were referred to our outpatient clinic for
the first time. The diagnosis relied on duodenal biopsy
and serology as well as HLA typing when indicated. Small
intestinal biopsies (n = 5 samples), taken from the bulb
and the second duodenal portion, were classified accord-
ing to Marsh-Oberhüber [16]. Serology included IgA anti-
TG2 and EmA together with IgG anti-TG2 or deamidated
gliadin peptide antibodies (DGP) in the case of IgA defi-
ciency [17]. Genetic testing, performed when there was
a discrepancy between histology and serology as well as
in selected cases, assessed HLA-DQ2 and-DQ8. The find-
ing of villous atrophy (including partial - 3a -, subtotal -
3b -, total atrophy - 3c) and positive serology confirmed
CD, whereas cases with positive serology and normal or
mild intestinal lesions (increased intra-epithelial lympho-
cytes - IEL - i.e. lesion type 1) were classified as potential
CD if HLA-DQ2 and/or -DQ8 tested positive. Cases with
villous atrophy, negative serology and positivity for HLA-
DQ2 and/or -DQ8 were confirmed as CD when a second
intestinal biopsy showed villous regrowth after 1-year
of GFD.
According to the Oslo classification, patients were clas-
sified as: 1) classical CD with malabsorptive syndrome,
i.e. diarrhea and weight loss irrespective of extraintestinal
manifestations; 2) non-classical CD with gastrointestinal
symptoms (except for diarrhea) and extraintestinal mani-
festations; 3) subclinical CD for clinically silent cases or
with symptoms below the threshold of detection [15].
Moreover, CD patients were investigated for pathologies
known to be frequently associated with CD (including
Hashimoto’s thyroiditis, type 1 diabetes mellitus -DM),
autoimmune liver disorders, connective tissue diseases,
neurological, allergic and chromosomal disorders) and were
followed up for the response to GFD and the occurrence of
complications [18].
Since patients were not individually identified, a sim-
plified International Review Board approval by the Ethics
Committee of the St. Orsola Malpighi Hospital was
obtained.
Statistical analysis
Statistical analysis was performed by applying Mann
Whitney U test to compare: 1) age of patients at diagnosis
in symptomatic (classical and non-classical) vs. subclinical
CD, as well as classical vs. non-classical phenotypes; 2) age
of patients at diagnosis in seropositive and seronegative
CD; 3) age of patients at diagnosis in complicated vs. non-
complicated CD. Moreover, the Pearson Chi-square test
was used to compare the clinical phenotype in seropositive
vs. seronegative CD patients and in complicated vs. non-
complicated CD. The above-mentioned statistical evalua-
tions were carried out by means of Graphpad Instant
Version3.0a (Graphpad Software Inc., San Diego, CA, USA).
Results
Clinical data
The annual distribution of CD diagnoses is shown in
Figure 1. Of the 770 CD patients, 318 were diagnosed in
the first 10 years (1998-2007), whereas 452 were detected
in the last five years (2008-2012). The onset of CD
was symptomatic in 610 patients (79%), whereas the
remaining 160 (21%) showed a subclinical phenotype.
Of the 610 symptomatic patients, 210 had the classical
phenotype, whereas 400 displayed the non-classical pheno-
type (Figure 2). In the period 1998-2007 the classical, non-
classical and subclinical phenotype were respectively found
in 47.2%, 43.1% and 9.7% of CD cases, whereas in the
period 2008-2012, the most frequent clinical phenotype
was the non-classical (58.2%), followed by the subclin-
ical (28.5%) and by the classical (13.3%). The median
age at diagnosis was significantly lower in patients with
the subclinical (32 years) than with the symptomatic
phenotype (37 years) (P < 0.001). No significant difference
was found in the median age at diagnosis between classical
and non-classical forms (39 vs. 36 years, P = 0.058). Taking
into account all CD patients (n = 770), about half (53%) of
them had gastrointestinal symptoms/manifestations, i.e.
diarrhea (27%), bloating (20%), aphthous stomatitis (18%),
alternating bowel habit (15%), constipation (13%) and
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gastroesophageal reflux disease (GERD) (12%) (Figure 3A).
Extra-intestinal manifestations, alone or in combination
with gastrointestinal symptoms, were detected in 45%
of CD patients (Figure 3B). Frequent findings were anemia
(34%), cryptogenic hypertransaminasemia (29%) and recur-
rent miscarriages (12%). A few CD patients showed IgE-
mediated allergy (9%), often characterized by positivity for
specific IgE to graminaceae and mites. A small number
of subjects showed headache (5%) and fibromyalgia-like
symptoms (2.2%). Iron-deficiency with low levels of
ferritin was found in 85% of patients with anemia, which
was also related to folic acid malabsorption. Bone densi-
tometry, performed in two-thirds of the 770 CD patients,
revealed a condition of osteopenia/osteoporosis in 52% of
cases, often associated with 25-OH Vitamin D3 low levels.
Serological tests
A total of 744 (97%) out of the 770 CD patients were
positive for IgA anti-TG2, whereas 91% of the same pa-
tients were IgA EmA positive. EmA detection was always
coincident with anti-TG2 positivity. Of the 26 patients
negative for IgA anti-TG2 and EmA, 15 had selective IgA
deficiency and all of them were positive for IgG anti-TG2
or DGP. Only 11 CD patients (9 females) were seronega-
tive. The median age at CD diagnosis was significantly
higher in the seronegative vs. seropositive patients (49
vs. 36 years, P < 0.005). Compared to seropositive cases,
CD patients testing negative for serology were all charac-
terized by a significantly higher prevalence of classical
phenotype (P < 0.001). Four seronegative patients showed
a positivity for first generation gliadin antibodies of IgG
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Figure 1 The annual distribution of CD diagnoses in the referral center of the St. Orsola-Malpighi University Hospital from 1998 to 2012.
Of the 770 diagnosed patients, 318 (41.2%) were identified in the first 10 years (1998-2007), whereas the other 452 (58.8%) were diagnosed in the last
five years (2008-2012).
Figure 2 Prevalence of symptomatic and subclinical phenotypes in the 770 CD patients. Note that 610 patients (79%) were diagnosed as
symptomatic, whereas the remaining 160 (21%) were classified as subclinical CD. Of the 610 symptomatic patients, 210 (34%) displayed the classical
onset with diarrhea and malabsorption (regardless of extraintestinal manifestations), whereas the other 400 showed the non-classical form
with gastrointestinal symptoms (other than diarrhea) and extraintestinal manifestations.
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class (1 case also associated with IgA), nowadays no longer
considered serological CD markers (Table 1).
Duodenal histology
Villous atrophy was found in 670 (87%) of 770 CD pa-
tients. Total (3c) and subtotal (3b) villous atrophy were
observed in 36% and in 26% of cases, respectively, whereas
a partial (3a) atrophy was identified in 25% of patients.
The remaining 100 patients (13%) had a histological pat-
tern characterized by an increased number of IEL (lesion
type 1). These minor lesions were consistent with a poten-
tial CD, confirmed by HLA-DQ2 and/or -DQ8 and IgA
anti-TG2 and/or EmA positivity. A high number of poten-
tial CD were first-degree relatives of CD and type 1 DM
patients. Only symptomatic cases of potential CD started
GFD, whereas subclinical cases continued to eat gluten.
Five out of the 100 potential CD cases showed disappear-
ance of EmA and anti-TG2 on a gluten containing diet.
Associated disorders
Autoimmune thyroiditis was found in 26.3% of CD
patients, of whom about half showed hypothyroidism.
Dermatitis herpetiformis was found in 4% of CD cases,
whereas type 1 DM was detectable in 3% of patients.
Other associated diseases included neurological disorders,
i.e. gluten ataxia, cryptogenic epilepsy and peripheral
neuropathy (all together 2.2%); IgA deficiency (1.9%);
autoimmune liver disorders, such as primary biliary cirrho-
sis and autoimmune hepatitis (1.8%). Finally, connective
tissue disorders, mainly Sjӧgren syndrome and systemic
A B
Figure 3 Gastrointestinal and extraintestinal symptoms in 770 CD patients. A) Symptoms related to gastrointestinal tract included diarrhea
(27%), bloating (20%), aphthous stomatitis (18%), alternate bowel habit (15%), constipation (13%) and gastroesophageal reflux disease (GERD)
(12%). B) Extraintestinal manifestations, alone or in combination with gastrointestinal symptoms/signs, included osteopenia/osteoporosis (52%),
anemia (34%), cryptogenic hypertransaminasemia (29%), recurrent miscarriages (12%), IgE-mediated allergy (9%), headache (5%) and fibromyalgia-like
symptoms (2.2%).
Table 1 Clinical presentation, histology, genetics and associated disorders in patients with seronegative celiac disease
Pts Gender Age at
diagnosis
Clinical
phenotype
HLA-
typing
Duodenal biopsy Anti-TG2 AGA Associated disorders
Untreated After GFD EmA DGP
#1 Male 58 Classical DQ2+ 3c 1 Neg IgG + ve Autoimmune thyroiditis
#2 Female 34 Classical DQ2+ 3a 1 Neg IgG + ve PBC
#3 Female 37 Classical DQ2+ 3c 1 Neg Neg None
#4 Female 75 Classical DQ2+ 3c 1 Neg Neg None
#5 Female 45 Classical DQ2+ 3a 1 Neg Neg None
#6 Female 55 Classical DQ2+ 3c 1 Neg IgG + ve Gluten ataxia
#7 Male 61 Classical DQ8+ 3b 1 Neg Neg Peripheral neuropathy
#8 Female 48 Classical DQ2+ 3c 1 Neg Neg None
#9 Female 49 Classical DQ2+ 3a 1 Neg IgG + ve; IgA + ve Autoimmune gastritis
#10 Female 30 Classical DQ2+ 3b 1 Neg Neg None
#11 Female 63 Classical DQ2+ 3c 1 Neg Neg None
Note: Anti-TG2: tissue transglutaminase antibodies, EmA: endomysial antibodies, DGP: deamidated gliadin antibodies, AGA: gliadin antibodies, GFD; gluten-free
diet, PBC; primary biliary cirrhosis; duodenal biopsy scored according to Marsh-Oberhüber classification: "3a", partial; "3b", subtotal; "3c", total villous atrophy; "1"
indicates increased intraepithelial lymphocytes.
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sclerosis were diagnosed in 1.7%. Chromosomal disor-
ders coexisted in 15 CD patients, i.e. 12 Down and 3
Turner syndrome. Only three celiac patients were af-
fected by inflammatory bowel disease (1 case of Crohn’s
disease ad 2 of ulcerative colitis).
Non-responsive CD
A total of 654 (85%) of the 770 CD patients underwent a
clinical and biochemical follow-up every 18 months. The
follow-up duration ranged from 18 months to 14 years
(mean 5 years). The response to GFD was regarded as
good in 514 patients (79%), whereas the remaining 140 CD
cases showed a poor response to GFD and were labeled as
non-responsive CD. The main causes of non-responsive
CD were poor compliance with GFD (40%), irritable bowel
syndrome (20%), GERD (15%), lactose intolerance (12%),
bacterial overgrowth (9%) and complicated CD (4%).
Complicated CD
Six (0.9%) of the 654 CD patients developed complications
during the follow-up (Table 2). Three patients had refrac-
tory CD type 1, two had small bowel carcinoma and
one developed enteropathy associated T cell lymphoma
(EATCL). Patients developing complications had a late
diagnosis with a median age of CD at diagnosis signifi-
cantly higher than that of non complicated CD (53.5 vs.
36 years, P < 0.005). The estimated diagnostic delay in
complicated CD cases ranged from 5 to 11 years. All
complicated CD had a classical phenotype testing positive
for HLA-DQ2 (3 cases carried DQ2 in homozygosis). Re-
garding clinical presentation, classical phenotype was
significantly higher in complicated vs. non complicated
CD (P < 0.001) (Table 2). Of the 6 complicated patients,
5 are still alive and only 1 with small bowel carcinoma
died 2 years after surgery and chemotherapy.
Discussion
The present study defines the clinical, serological and
histopathological features of CD in a large, single-
center series of consecutively diagnosed patients. Our
data highlighted a significant upward trend of diagnoses
over time. In the last 5 years the number of CD diagnoses
was one and half times higher than that in the previous
ten years. The clinical presentation of CD changed over
time with a marked decrease of the classical phenotype
(from 47.2% in the first 10 years to 13.3% in the last five
years) and with a striking increase of the non-classical and
subclinical phenotype which characterized the onset of
CD in more than 86% of cases in the last five years. CD
was more frequently found in females with a female/male
ratio of 3.5:1, a figure that confirms well established data
[19]. The median age of CD at diagnosis was between the
third and the fourth decade of life, but 5% of our patients
were diagnosed in the elderly. These late-onset cases,
which were not explained as diagnostic delay, confirm
that the disease can occur at any age [20]. CD patients
were clinically stratified on the basis of the Oslo classi-
fication and, accordingly, the vast majority (79%) were
symptomatic. One third showed the classical form of
the disease characterized by diarrhea and malabsorption,
while the remaining two thirds were labeled as non-classical
complaining of atypical gastrointestinal and extraintes-
tinal manifestations. Notably, diarrhea should be no longer
regarded as the cardinal symptom of CD [13]. Although
there are no comparative studies on the prevalence of
symptoms/manifestations (e.g., bloating, alternating bowel
habit, constipation and GERD) in functional bowel disor-
ders and CD patients, we demonstrated such symptoms
in about 20% of cases suggesting a link between gastro-
intestinal functional impairment and CD. Confirmatory
screening tests for CD should be proposed to patients with
functional bowel symptoms, in particular to those people
living in areas with high CD prevalence [21]. Frequent
extraintestinal manifestations raising suspicion of CD
were anemia (due to iron and, less frequently, folic acid
deficiency), cryptogenic hypertransaminasemia and recur-
rent miscarriages. An unexplained osteopenia/osteoporosis
was an indicator of CD, being present in more than 50% of
cases. One fifth of the 770 CD patients were classified as
having subclinical CD. This subgroup has progressively
increased in recent years due to the use of serological
Table 2 Clinical and genetic features of the 6 celiac disease patients developing complications
Pts Gender Age at diagnosis (yrs) Clinical
phenotype
HLA Delay in CD
diagnosis (yrs)
Age at complication (yrs) Complication Outcome
#1 M 42 Classical DQ2 + ° 8 45 EATCL Alive, 54 yrs
#2 F 66 Classical DQ2+ 10 70 RCD type 1 Alive, 73 yrs
#3 F 52 Classical DQ2 + ° 5 56 RCD type 1 Alive, 64 yrs
#4 F 48 Classical DQ2+ 6 51 Small bowel carcinoma Dead, 53 yrs
#5 F 65 Classical DQ2 + ° 11 65 Small bowel carcinoma Alive, 76 yrs
#6 F 55 Classical DQ2+ 7 59 RCD type 1 Alive, 66 yrs
EATCL, enteropathy associated T-cell lymphoma; RCD, refractory celiac disease.
°DQ2 homozygosis (DQB1 *0201 on both chromosomes) was established in case #1, #3 and #5.
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screening. Interestingly, the age at CD diagnosis was
significantly lower in subclinical than in symptomatic
CD, thus suggesting that serological screening detects
CD earlier than symptoms.
Our series confirmed that IgA anti-TG2 were more
sensitive than IgA EmA for the diagnosis of CD [2]. Other
important findings included that IgA EmA positivity was
never found in cases without IgA anti-TG2 [22]; about
two thirds of the IgA TG2/EmA negative cases had IgA
deficiency (and tested positive for IgG anti-TG2/DGP)
[17] and, finally, that seronegative CD was identified only
in a small subset of patients (1.4%) [23]. Seronegative
patients showed peculiar aspects not fully reported in
previous studies [24]. First, compared to seropositive CD,
seronegative disease was significantly associated with a
classical phenotype. Thus, in all malabsorptive patients a
diagnosis of CD should be always ruled out by small bowel
biopsy regardless an unsupportive serological profile.
Secondly, seronegative CD was characterized by a more
pronounced prevalence of the female gender (F/M 4.5:1)
and a significantly higher median age at diagnosis (49 years)
than seropositive CD (F/M 3.5:1 and 36 years). Thirdly, a
close association with autoimmune disorders including
primary biliary cirrhosis, autoimmune gastritis, Hashimoto's
thyroiditis, peripheral neuropathy and gluten ataxia was
found in seronegative patients. Finally, a proportion of
otherwise seronegative CD patients tested positive for IgG
AGA, a notoriously aspecific marker of CD [25], which,
however, in the presence of villous atrophy may be clinic-
ally useful to address the diagnosis [26].
Compared to previous studies showing frequent flat
mucosa [27], our data showed that only 62% of CD pa-
tients had severe intestinal damage (type 3b, 3c), whereas
partial atrophy (type 3a) was found in an increasing per-
centage of cases (25%). The latter finding may be the
result of early detection of CD in a stage when intestinal
damage has not yet peaked. Furthermore, in parallel with
partial intestinal atrophy, the number of potential CD cases
(13%) was also high. The possible disappearance of sero-
logical markers in patients with potential CD on a gluten-
containing diet particularly in subclinical patients, suggests
a cautionary approach before starting GFD [28]. Another
aspect pertaining to histopathology is related to the new
guidelines emanated by ESPGHAN. Following these
criteria it is now possible to skip histopathologic evaluation
and to establish CD diagnosis in symptomatic children and
adolescents testing positive for high titer anti-TG2 (more
than ten folds above the cut-off) and confirmed by EmA
and HLA-DQ2 and/or -DQ8 positivity [29]. Our series
indicates that the ESPGHAN criteria, although quite inter-
esting and certainly useful in the pediatric age, cannot be
applied in adult CD cases [30,31]. In fact, a minority of
cases with high titer anti-TG2 (>10 times the upper normal
limit) had non-atrophic mucosa being classifiable as a
potential CD, implying that in adult patients a firm diag-
nosis should always be established by means of small in-
testinal biopsy.
Our data confirm and expand the concept that CD can
be associated with a number of autoimmune diseases [32].
A possible explanation for this spread of autoimmunity
occurring in CD may be the ubiquitous distribution of
TG2 in many other organs and tissues besides the small
bowel [33]. Our study indicated that the most frequent
condition associated with CD was Hashimoto's thyroiditis,
found in about in one fourth of cases, with half of them de-
veloping clinical hypothyroidism. Dermatitis herpetiformis
and type 1 DM were detected in 4% and 3% of CD pa-
tients, respectively, both percentages in line with previ-
ous studies [34,35]. Concerning type 1 DM, previous data
have shown that it rarely occurs in CD patients on a strict
GFD, suggesting that gluten withdrawal may exert a
protective role [36]. Brain and liver autoimmune disorders
were closely associated with CD as shown by gluten
ataxia, peripheral neuropathy, epilepsy (notably resistant
to pharmacologic treatment), primary biliary cirrhosis and
autoimmune hepatitis identified in our CD patients
[37-39]. Concerning connective tissue disorders our data
confirmed that Sjӧgren syndrome and, to a lesser extent,
systemic sclerosis were closely related to CD [40,41],
whereas, as previously reported, systemic lupus erythe-
matosus and rheumatoid arthritis were rarely detected
in CD [42,43]. As previously demonstrated, Down and, to a
lower extent, Turner syndrome were the two chromosomal
disorders most commonly associated with CD [44,45].
An emerging entity is the non-responsive CD, which
includes patients with an unsatisfactory response to GFD
[46]. In our study we evaluated the response to GFD in
654 CD patients, followed-up for a period ranging from
18 months to 14 years. About 20% of them were labeled
as non-responsive CD due to poor compliance to GFD,
functional gastrointestinal disorders (e.g. GERD and ir-
ritable bowel syndrome) as well as food intolerance, e.g.
to lactose. Another cause of non-responsive CD reported
in the literature, i.e. CD misdiagnosis, was not identified in
our series since all patients had been diagnosed according
to well-established criteria [47]. The lack of response to
GFD can be also due to the onset of complications in the
natural course of CD. For many years the frequency of
complicated CD has been overestimated with data ranging
up to 10% of the total number of celiac patients. Recent
data, however, clearly demonstrated that complications
occur in about 1% of CD patients [18,48] and, in the
present study, only 0.9% of CD patients developed a
complication including 3 cases of refractory CD, 2 small
bowel carcinoma and 1 case of EATCL. The risk for the
development of complications was higher in patients with
a late recognition of CD and with a significant diagnostic
delay. Complicated CD showed a significantly higher
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median age at diagnosis than non-complicated CD. More-
over, the occurrence of complications in CD patients was
significantly related with an onset of CD characterized by
the classical form with diarrhea and malabsorption, sug-
gesting that non-classical and subclinical forms are at a
lower risk of developing complications. CD patients with
HLA-DQ2 homozygosis display a higher risk of develop-
ing complications [49]. Surprisingly, the prognosis of com-
plicated CD in our series was better than expected with
5 of the 6 patients still alive after a mean follow-up of
10 years.
Possible limitations of this study concerned its retro-
spective nature which might have biased the data analysis
as well as the lack of information on pediatric cases of CD.
Conclusions
In conclusion, this study detailed the clinical features, ser-
ology and histopathological data in a very large series of
adult CD patients diagnosed in a single referral center over
a 15 year time frame. The results of this series corrobo-
rated and expanded previous evidence regarding: i) the
clinical presentation of CD according to recently defined
criteria (i.e. non-classical and subclinical prevailed over the
classical forms); ii) the possibility of establishing an early
diagnosis (i.e. when the disease is still in a preclinical/
paucisymptomatic stage), hence justifying an increased
number of potential CD cases; iii) the different serological
and histological patterns of the disease, which can help in
the diagnostic work-up; and iv) the identification of auto-
immune disorders commonly associated with CD. Finally,
the follow-up of our CD patients showed that a high pro-
portion of cases (about 20%) could be labeled as non-
responsive CD, mainly because of low compliance to GFD
or concomitant functional gastrointestinal disorders. The
lack of responsiveness can be related to complications,
which, although rare, require an early diagnosis in order
to avoid a poor outcome.
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